Advances in Medicinal Chemistry, Volume 3Edited by
- B.E. Maryanoff, Medicinal Chemistry Department, R.W. Johnson Pharmaceutical Research Institute, Springhouse, Pennsylvania, USA
- C.A. Maryanoff, Chemical Development Department, R.W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA
Volume 3 of Advances in Medicinal Chemistry is comprised of four chapters on diverse aspects of medicinal chemistry. Chapter 1 presents an account of a research program which was started to discover a novel antipsychotic agent with minimal side effects for the treatment, principally, of schizophrenia. Chapter 2 relates an account on the discovery of novel antithrombotic drugs based on the RGD motif through a rational design approach. Chapter 3 presents the medicinal chemistry and preclinical development surrounding sertraline, a very important serotonin reuptake drug for the treatment of endogenous depression. Finally, Chapter 4 gives a summary of a series of boronic acid-based immunosuppressants that operate via inhibition of dipeptidypeptidase IV.
Advances in Medicinal Chemistry
Published: December 1995
REVIEW: "In summary, the third volume of this series continues to offer well written, interesting accounts of topics important to the discipline of medicinal chemistry and with up-to-date references. Some of the chapters seem well suited as special topics in graduate courses. This series should appeal to a broad audience of researchers, teachers, and students".
Journal of American Chemical Society
- List of Contributors.
Preface (B.E. Maryanoff and C.A. Maryanoff).
1. Novel Antipsychotics with Unique D2/5-HT1A Affinity and Minimal Extrapyramidal Side Effect Liability (A.B. Reitz and M.K. Scott).
2. Antiplatelet and Antithrombotic Agents: from Viper Venom Proteins, to Peptides and Peptidomimetics, to Small Organic Molecules (P.L. Barker and R.R. Webb, II).
3. Discovery and Preclinical Development of the Serotonin Reuptake Inhibitor Sertraline (W.M. Welch).
4. Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: A New Class of Immunosuppressive Agents (R.J. Snow and W.W. Bachovchin).